Is there still a role for hormonal therapy?

International Journal of Gynecological Cancer

Volumn 15, Issue 6 SUPPL. 3, 2005, Pages 291-297

  Bookman, Michael A ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Hormone therapy; Ovarian cancer; Tamoxifen

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; CA 125 ANTIGEN; CISPLATIN; DOXORUBICIN; ESTROGEN; GONADORELIN AGONIST; LETROZOLE; MEGESTROL; PLATINUM; RALOXIFENE; TAMOXIFEN;

BREAST CANCER; CANCER RECURRENCE; CANCER RISK; CHEMOPROPHYLAXIS; HIGH RISK PATIENT; HORMONAL THERAPY; HORMONE RESPONSE; HORMONE SUBSTITUTION; HUMAN; MOLECULAR INTERACTION; OVARY CANCER; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SURVIVAL RATE; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; HUMANS; OVARIAN NEOPLASMS; POSTMENOPAUSE; PREMENOPAUSE; RECEPTORS, ESTROGEN;

EID: 30744466455     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2005.00442.x     Document Type: Review

References (41)

1. Makar AP. Hormone therapy in epithelial ovarian cancer. Endocr Relat Cancer 2000;7:85-93.
2. Fathalla MF. Incessant ovulation-a factor in ovarian neoplasia? Lancet 1971;2:163.
3. Wu ML, Whittemore AS, Paffenbarger JR et al. Personal and environmental characteristics related to epithelial ovarian cancer in reproductive and menstrual events and oral contraceptive use. Am J Epidemiol 1988;6:1216-27.
4. Gwin ML, Lee N, Rhodes PH, Layde PM, Rubin G. Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer. J Clin Epidemiol 1989;43:559-68.
5. Risch HA, Weiss NH, Lyon JL. Events of reproductive life and the incidence of epithelial ovarian cancer. Am J Epidemiol 1983;117:1128-39.
6. Cunat S, Hoffmann P, Pujol P. Estrogens and epithelial ovarian cancer. Gynecol Oncol 2004;94:25-32.
7. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001;285:1460-5.
8. Lacey JV Jr, Mink PJ, Lubin JH et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002;288:334-41.
9. Cook LS, Weiss NS, Schwartz SM et al. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst 1995;87:1359-64.
10. McGonigle KF, Vasilev SA, Odom-Maryon T, Simpson JF. Ovarian histopathology in breast cancer patients receiving tamoxifen. Gynecol Oncol 1999;73:402-6.
11. Neven P, Goldstein SR, Ciaccia AV, Zhou L, Silfen SL, Muram D. The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women. Gynecol Oncol 2002;85:388-90.
12. Hua W, Christianson T, Rougeot C, Rochefort H, Clinton GM. SKOV3 ovarian carcinoma cells have functional estrogen receptor but are growth-resistant to estrogen and antiestrogens. J Steroid Biochem Mol Biol 1995;55:279-89.
13. Guidozzi F, Daponte A. Estrogen replacement therapy in ovarian cancer survivors: a randomized controlled trial. Cancer 1999;86:1013-8.
14. Long RTL, Evans AM. Diethylstilbestrol as a chemotherapeutic agent for ovarian cancer. Mod Med 1963;60:1125-7.
15. Fiorica JV, Brunetto VL, Hanjani P, Lentz SS, Mannel R, Andersen W. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:10-4.
16. Perez-Gracia JL, Carrasco EM. Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research. Gynecol Oncol 2002;84:201-9.
17. Markman M, Iseminger KA, Hatch KD, Creasman WT, Barnes W, Dubeshter B. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group ancillary report. Gynecol Oncol 1996;62:4-6.
18. Trope C, Marth C, Kaern J. Tamoxifen in the treatment of recurrent ovarian carcinoma. Eur J Cancer 2000;36(Suppl. 4):59s-61s.
19. Van Der Velden J, Gitsch G, Wain GV, Friedlander ML, Hacker NF. Tamoxifen in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 1995;5:301-5.
20. van der Vange N, Greggi S, Burger CW, Kenemans P, Vermerken JB. Experience with hormonal therapy in advanced epithelial ovarian cancer. Acta Oncol 1995;34:813-20.
21. Paskeviciute L, Roed H, Engelholm S. No rules without exception: long-term complete remission observed in a study using a LH-RH agonist in platinum-refractory ovarian cancer. Gynecol Oncol 2002;86:297-301.
22. Hofstra LS, Mourits MJ, de Vries EG, Mulder NH, Willemse PH. Combined treatment with goserelin and tamoxifen in patients with advanced chemotherapy resistant ovarian cancer. Anticancer Res 1999;19:3627-30.
23. Rose PG, Reale FR, Longcope C, Hunter RE. Prognostic significance of estrogen and progesterone receptors in epithelial ovarian cancer. Obstet Gynecol 1990;76:258-63.
24. Markman M, Webster K, Zanotti K, Rohl J, Belinson J. Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer. Gynecol Oncol 2004;93:390-3.
25. McClay EF, Albright KD, Jones JA, Christen RD, Howell SB. Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines. Br J Cancer 1994;70:449-52.
26. Kikuchi Y, Hirata J, Kita T, Imaizumi E, Tode T, Nagata I. Enhancement of antiproliferative effect of cis-diamminedichloroplatinum(II) by clomiphene and tamoxifen in human ovarian cancer cells. Gynecol Oncol 1993;49:365-72.
27. Schwartz PE, Chambers JT, Kohorn EI et al. Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial. Cancer 1989;63:1074-8.
28. Benedetti Panici P, Greggi S, Amoroso M et al. A combination of platinum and tamoxifen in advanced ovarian cancer failing platinum-based chemotherapy: results of a Phase II study. Int J Gynecol Cancer 2001;11:438-44.
29. Markman M, Webster K, Zanotti K, Peterson G, Kulp B, Belinson J. Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum. Gynecol Oncol 2004;94:404-8.
30. Choi KC, Kang SK, Tai CJ, Auersperg N, Leung PC. Estradiol up-regulates antiapoptotic Bcl-2 messenger ribonucleic acid and protein in tumorigenic ovarian surface epithelium cells. Endocrinology 2001;142:2351-60.
31. Mabuchi S, Ohmichi M, Kimura A et al. Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase cascades in human ovarian cancer cell lines in a manner not dependent on the expression of estrogen receptor or the sensitivity to cisplatin. Endocrinology 2004;145:1302-13.
32. Kelley KM, Rowan BG, Ratnam M. Modulation of the folate receptor alpha gene by the estrogen receptor: mechanism and implications in tumor targeting. Cancer Res 2003;63:2820-8.
33. Schiff R, Massarweh SA, Shou J et al. Cross-talk between estrogen receptor and growth factor receptor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004;10:331s-336s.
34. Shou J, Massarweh S, Osborne CK et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004;96:926-35.
35. De Placido S, De Laurentiis M, Carlomagno C et al. Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 2003;9:1039-46.
36. Chu I, Blackwell K, Chen S, Slingerland J. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 2005;65:18-25.
37. Bowman A, Gabra H, Langdon SP et al. CA125 response is associated with estrogen receptor expression in a phase II trial of Letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res 2002;8:2233-9.
38. Osipo C, Gajdos C, Liu H, Chen B, Jordan VC. Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst 2003;95:1597-608.
39. Jordan VC. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. J Med Chem 2003;46:1081-111.
40. Liu H, Lee ES, Gajdos C et al. Apoptotic action of 17β-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst 2003;95:1586-97.
41. Jordan VC. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 2004;5:207-13.